Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05710679

Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer

Sixty percent of newly diagnosed head and neck squamous cell carcinomas (HNSCCs) are at a locally advanced (LA) stage. Depending on tumor site, stage, and resectability, locoregional failure rates can range from 35% to 65%. The persistence of residual disease at the end of treatment is a major prognostic element but is not always reliably assessed by current imaging techniques. Up to 40-50% of patients have residual adenomegaly and only 30% have viable disease when further adenectomy is performed. Sensitive and reproducible detection of residual disease after treatment is a major challenge in this patient category.

18F-fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET/CT) guided surveillance, with a negative predictive value of 95-97%, has proven to be non-inferior to cervical curage in HNSCCs with residual adenomegaly. Cervical curage is now indicated only if the response assessed by PET-CT is incomplete. Nevertheless, the ability of PET-CT to predict treatment failure is unsatisfactory due to a high frequency of false positives, because of inflammatory changes, with a positive predictive value of about 20-50%.

Circulating tumor DNA (ctDNA) may provide a more reliable assessment of response to potentiated radiotherapy. Liquid biopsy monitoring of response in patients treated with potentiated radiation therapy for locally advanced HNSCCs a has been shown to be feasible. In 85% of patients, ctDNA is detectable and correlates significantly with tumor volume and response to treatment. In addition, one study showed that post-radiotherapy analysis of circulating HPV16 viral DNA (cvDNA) in patients with HPV16-related HNSCCs complemented PET-CT and helped guide management decisions. HPV16 cvDNA and PET-CT have similar negative predictive values, whereas the positive predictive value is higher for HPV16 cvDNA (100% versus 50%). Nevertheless, current data are insufficient to allow routine use of this marker.

This is a multicenter, single arm, open study for patients with a locally advanced head and neck cancer for which a potentiated radiotherapy is indicated.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Locally Advanced Head and Neck Carcinoma

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Jean PERRIN, Clermont-Ferrand, Puy-de-Dôme, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years and ≤ 80 years
  • Histologically confirmed, never treated squamous cell carcinoma with lymph node involvement
  • squamous cell carcinoma p16+or p16-, stage III (N1), IVa or IVb (UICC classification 8th edition), N1 minimum, and oropharyngeal sqamous cell carcinomas p16+ stage I or II, N1 minimum, resectable but not operated or unresectable, with indication for concomitant or sequential radiochemotherapy with induction chemotherapy using Docetaxel, Platinum, 5-Fluorouracil (TPF or modified TPF according to the practices of the investigating centers)
  • Oral cavity, oropharynx, hypopharynx or larynx, cervical adenopathies without primary
  • Availability of FFPE samples prior to treatment initiation
  • Detection of circulating DNA in the initial blood sample
  • Obtaining informed consent from the patient
  • Affiliation to the French social security system

Exclusion criteria

  • Tumor of the nasopharynx, sinuses, nasal cavity, salivary glands or thyroid cancer
  • Treatment by exclusive radiotherapy
  • Contraindication to cervical lymph node dissection
  • Metastatic disease (stage IVc)
  • Previous treatment for head and neck cancer
  • History of other cancer in the last 3 years (except carcinoma in situ, basal cell skin carcinoma, localized prostate cancer Gleason 6)
  • Pregnant or breastfeeding woman
  • Patient under guardianship or curators
  • Psychological disorder (cognitive disorders, vigilance disorders, etc.) or social reasons (deprivation of liberty by judicial or administrative decision) or geographical reasons that could compromise the medical follow-up of the trial or compliance with the treatment

Treatment and study plan

Blood sample

Biological

The intervention consist in a blood sample that will be taken twice :

  • at the inclusion (before treatment)
  • 3 months after the radiochemotherapy in case of incomplete response (PET-CT)

Primary outcomes

  1. Rate of patients with incomplete cervical lymph node response on PET-CT after radiochemotherapy having circulating DNA (cDNA)

    Time frame: 3 months after potentiated radiotherapy

    Presence/absence of circulating DNA after treatment versus presence/absence of residual disease

Secondary outcomes

  1. cDNA detection rate among patients with residual adenomegaly after treatment

    Time frame: at three-months after potentiated radiotherapy.

    The detection of cDNA and response on CT-Scan will be compared

  2. Assessment of the prognostic value of cDNA detection 3 months after the end of radiochemotherapy for patients with residual adenomegaly

    Time frame: at three-months after potentiated radiotherapy.

    Evaluated by overall and progression-free survival

  3. Assessment of the prognosis value of the presence of residual adenomegaly

    Time frame: At month 27

    Evaluated by overall and progression-free survival

  4. Rate of concordance of mutational profiles and Human papillomavirus-high risk (HPV-HR) genotypes between the primary tumor and cDNAs at diagnosis

    Time frame: Inclusion

    evaluated the mutational profiles from FFPE block and the inclusion blood sample

  5. Rate of concordance between p16 immunohistochemistry and HPV-HR genotyping on the primary tumor

    Time frame: Inclusion

  6. Test of the concordance between real-time polymerase chain reaction (PCR) and NGS on formalin-fixed paraffin-embedded (FFPE) for simultaneous detection and genotyping of HPV-HR at diagnosis

    Time frame: Inclusion

  7. Number of patients with ctDNA and cvDNA detection at diagnosis and the clinical, paraclinical and pathological features of the cancer

    Time frame: Through study completion, an average of 66 months

  8. Evaluation of interobserver reproducibility of the interpretation of SUVmax measurements of residual cervical adenomegaly.

    Time frame: 3 months after potentiated radiotherapy

    A centralized review of the PET-CT will be done by the sponsor to evaluate the reproducibility of the interpretation of SUVmax measurements of residual cervixal adenomegaly (pathological/benign/equivocal)

Study contacts

Contact information is provided by the study sponsor or research team.

Angeline GINZAC COUVÉ, PhD

CONTACT

[email protected]

0463663337 ext. +33

Sponsors and collaborators

Lead sponsor

Centre Jean Perrin

Other

Collaborators

  • GIRCI Auvergne Rhone-Alpes

Registry information

Acronym: NeckTAR

Important dates

Study start
2024
Primary completion
2029
Study completion
2031
First posted
Feb 2, 2023
Registry last updated
May 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.